89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer-Reference-Cited by-同舟云学术

89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer

Published:2018-11-26 Issue:12 Volume:24 Page:1852-1858
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Bensch Frederike,van der Veen Elly L.,Lub-de Hooge Marjolijn N.,Jorritsma-Smit Annelies,Boellaard Ronald,Kok Iris C.,Oosting Sjoukje F.,Schröder Carolina P.,Hiltermann T. Jeroen N.,van der Wekken Anthonie J.,Groen Harry J. M.,Kwee Thomas C.,Elias Sjoerd G.,Gietema Jourik A.,Bohorquez Sandra Sanabria,de Crespigny Alex,Williams Simon-Peter,Mancao Christoph,Brouwers Adrienne H.,Fine Bernard M.^ORCID,de Vries Elisabeth G. E.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/s41591-018-0255-8.pdf

Reference41 articles.

1. Balar, A. V. et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 389, 67–76 (2017).

2. Daud, A. I. et al. Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. J. Clin. Oncol. 34, 4102–4109 (2016).

3. Hegde, P. S., Karanikas, V. & Evers, S. The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin. Cancer Res. 22, 1865–1874 (2016).

4. Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387, 1909–1920 (2016).

5. Chen, P. L. et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov. 6, 827–837 (2016).

Cited by 512 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative study of [18F]AlF-PAI-PDL1p and [68Ga]Ga-PAI-PDL1p as novel PD-L1 targeting PET probes for tumor imaging;Bioorganic Chemistry;2024-10

2. Targeting tumour metabolism in melanoma to enhance response to immune checkpoint inhibition: A balancing act;Cancer Treatment Reviews;2024-09

3. Trends in cancer imaging;Trends in Cancer;2024-09

4. Preliminary Research of Radiolabeled Atezolizumab for the Noninvasive Evaluation of TNBC PD‐L1 Expression In Vivo;Journal of Labelled Compounds and Radiopharmaceuticals;2024-08-30

5. Multispectral fluorescence imaging of EGFR and PD-L1 for precision detection of oral squamous cell carcinoma: a preclinical and clinical study;BMC Medicine;2024-08-26